Zacks Investment Research downgraded shares of CytoDyn (OTCMKTS:CYDY) from a hold rating to a sell rating in a report issued on Monday morning.

According to Zacks, “CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. “

Separately, HC Wainwright reiterated a buy rating on shares of CytoDyn in a research note on Wednesday, November 29th.

CytoDyn (OTCMKTS CYDY) opened at $0.73 on Monday. CytoDyn has a one year low of $0.46 and a one year high of $0.84. The stock has a market cap of $136.14, a PE ratio of -2.92 and a beta of 0.82.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/15/cytodyn-cydy-downgraded-to-sell-at-zacks-investment-research-2.html.

CytoDyn Company Profile

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

Get a free copy of the Zacks research report on CytoDyn (CYDY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.